Blood clot drug trial for rare autoimmune disease pulled before start
NCT ID NCT07172022
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 27 times
Summary
This study aimed to test if crovalimab, added to standard blood thinners, could prevent dangerous blood clots in people with antiphospholipid syndrome (APS). APS is an autoimmune condition that raises the risk of clots. The trial was planned for adults aged 18–70 with at least two prior clots, but it was withdrawn before enrolling anyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.